Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS
Abstract
:1. Introduction
2. Treatment as Prevention
3. Pre-Exposure Prophylaxis
4. Antiretroviral Therapy and PrEP Programs in British Columbia
5. The Basic Reproduction Number ()
Characterizing the Impact of TasP and PrEP on
6. TasP + PrEP in Other Jurisdictions
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Carpenter, C.C.; Fischl, M.A.; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S.; Richman, D.D.; Saag, M.S.; Schooley, R.T.; et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276, 146–154. [Google Scholar] [CrossRef] [PubMed]
- Gandhi, R.T.; Bedimo, R.; Hoy, J.F.; Landovitz, R.J.; Smith, D.M.; Eaton, E.F.; Lehmann, C.; Springer, S.A.; Sax, P.E.; Thompson, M.A.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023, 329, 63–84. [Google Scholar] [CrossRef]
- Lima, V.D.; Hogg, R.S.; Harrigan, P.R.; Moore, D.; Yip, B.; Wood, E.; Montaner, J.S. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007, 21, 685–692. [Google Scholar] [CrossRef]
- Marcus, J.L.; Chao, C.R.; Leyden, W.A.; Xu, L.; Quesenberry, C.P.J.; Klein, D.B.; Towner, W.J.; Horberg, M.A.M.; Silverberg, M.J. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J. Acquir. Immune Defic. Syndr. 2016, 73, 39–46. [Google Scholar] [CrossRef]
- Montaner, J.; Hogg, R.; Wood, E.; Kerr, T.; Tyndall, M.; Levy, A.R.; Harrigan, P.R. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006, 368, 531–536. [Google Scholar] [CrossRef]
- Granich, R.M.; Gilks, C.F.; Dye, C.; De Cock, K.M.; Williams, B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009, 373, 48–57. [Google Scholar] [CrossRef]
- Salomon, J.A.; Hogan, D.R.; Stover, J.; Stanecki, K.A.; Walker, N.; Ghys, P.D.; Schwartländer, B. Integrating HIV prevention and treatment: From slogans to impact. PLoS Med. 2005, 2, e16. [Google Scholar] [CrossRef] [PubMed]
- Bunnell, R.; Ekwaru, J.P.; Solberg, P.; Wamai, N.; Bikaako-Kajura, W.; Were, W.; Coutinho, A.; Liechty, C.; Madraa, E.; Rutherford, G.; et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006, 20, 85–92. [Google Scholar] [CrossRef] [PubMed]
- Cu-Uvin, S.; Caliendo, A.M.; Reinert, S.; Chang, A.; Juliano-Remollino, C.; Flanigan, T.P.; Mayer, K.H.; Carpenter, C.C.J. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000, 14, 415–421. [Google Scholar] [CrossRef]
- Vernazza, P.L.; Gilliam, B.L.; Flepp, M.; Dyer, J.R.; Frank, A.C.; Fiscus, S.A.; Cohen, M.S.; Eron, J.J. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997, 11, 1249–1254. [Google Scholar] [CrossRef]
- Fang, G.; Burger, H.; Grimson, R.; Tropper, P.; Nachman, S.; Mayers, D.; Weislow, O.; Moore, R.; Reyelt, C.; Hutcheon, N. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc. Natl. Acad. Sci. USA 1995, 92, 12100–12104. [Google Scholar] [CrossRef]
- Vernazza, P.; Hirschel, B.; Bernasconi, E.; Flepp, M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficacene transmettent pas le VIH par voie sexuelle. Bull. Med. Svizz. 2008, 89, 165–169. [Google Scholar] [CrossRef]
- Del Romero, J.; Castilla, J.; Hernando, V.; Rodriguez, C.; Garcia, S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: Cross sectional and prospective cohort study. BMJ 2010, 340, c2205. [Google Scholar] [CrossRef]
- Donnell, D.; Baeten, J.M.; Kiarie, J.; Thomas, K.K.; Stevens, W.; Cohen, C.R.; McIntyre, J.; Lingappa, J.R.; Celum, C. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010, 375, 2092–2098. [Google Scholar] [CrossRef] [PubMed]
- Rodger, A.J.; Cambiano, V.; Bruun, T.; Vernazza, P.; Collins, S.; Degen, O.; Corbelli, G.M.; Estrada, V.; Geretti, A.M.; Beloukas, A.; et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. Lancet 2019, 393, 2428–2438. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Ge, Z.; Juo, J.; Shan, D.; Gao, X.; Ding, G.; Zhou, J.; He, W.; Wang, N. HIV transmission risk among serodiscordant couples: A retrospective study of former plasma donors in Henan, China. J. Acquir. Immune Defic. Syndr. 2010, 55, 232–238. [Google Scholar] [CrossRef]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.; et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365, 493–505. [Google Scholar] [CrossRef] [PubMed]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.; et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N. Engl. J. Med. 2016, 375, 830–839. [Google Scholar] [CrossRef]
- Broyles, L.N.; Luo, R.; Boeras, D.; Vojnov, L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: A systematic review. Lancet 2023, 402, 464–471. [Google Scholar] [CrossRef]
- Bekker, L.G.; Smith, P.; Ntusi, N.A.B. HIV is sexually untransmittable when viral load is undetectable. Lancet 2023, 402, 428–429. [Google Scholar] [CrossRef]
- Sidibé, M. AIDS at the Tipping Point: Herculean Challenges; Olympian Benefits. Available online: https://www.unaids.org/sites/default/files/media_asset/20100226_sp_sidibe_vancouver_en_0.pdf (accessed on 13 September 2023).
- WHO/UNAIDS. The Treatment 2.0 Framework for Action: Catalyzing the Next Phase of Treatment, Care, and Support. Available online: https://www.unaids.org/sites/default/files/media_asset/20110824_JC2208_outlook_treatment2.0_en_0.pdf (accessed on 13 September 2023).
- UNAIDS. 90-90-90: Treatment for All. Available online: https://www.unaids.org/en/resources/909090#:~:text=By%202020%2C%2090%25%20of%20all,therapy%20will%20have%20viral%20suppression (accessed on 13 September 2023).
- UNAIDS. 2025 AIDS TARGETS. Available online: https://www.unaids.org/sites/default/files/2025-AIDS-Targets_en.pdf (accessed on 13 September 2023).
- Stover, J.; Hallett, T.B.; Wu, Z.; Warren, M.; Gopalappa, C.; Pretorius, C.; Ghys, P.D.; Montaner, J.; Schwartländer, B.; The New Prevention Technology Study Group. How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS ONE 2014, 9, e111956. [Google Scholar] [CrossRef] [PubMed]
- Grant, R.M.; Lama, J.R.; Anderson, P.L.; McMahan, V.; Liu, A.Y.; Vargas, L.; Goicochea, P.; Casapía, M.; Guanira-Carranza, J.V.; Ramirez-Cardich, M.E.; et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010, 363, 2587–2599. [Google Scholar] [CrossRef] [PubMed]
- Anderson, P.L.; Glidden, D.V.; Liu, A.; Buchbinder, S.; Lama, J.R.; Guanira, J.V.; McMahan, V.; Bushman, L.R.; Casapía, M.; Montoya-Herrera, O.; et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 2012, 4, 151ra125. [Google Scholar] [CrossRef] [PubMed]
- Molina, J.M.; Capitant, C.; Spire, B.; Pialoux, G.; Cotte, L.; Charreau, I.; Tremblay, C.; Le Gall, J.-M.; Cua, E.; Pasquet, A.; et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N. Engl. J. Med. 2015, 373, 2237–2246. [Google Scholar] [CrossRef]
- Molina, J.M.; Charreau, I.; Spire, B.; Pialoux, G.; Cotte, L.; Charreau, I.; Tremblay, C.; Le Gall, J.-M.; Cua, E.; Pasquet, A.; et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: An observational cohort study. Lancet HIV 2017, 4, e402–e410. [Google Scholar] [CrossRef]
- Marrazzo, J.M.; Ramjee, G.; Richardson, B.A.; Gomez, K.; Mgodi, N.; Nair, G.; Palanee, T.; Nakabiito, C.; van der Straten, A.; Noguchi, L.; et al. VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 2015, 372, 509–518. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- British Columbia Centre for Excellence in HIV/AIDS. Guidance for the Use of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV Acquisition in British Columbia. Available online: https://bccfe.ca/wp-content/uploads/2023/12/prep_guidelines_17-jun-2020.pdf (accessed on 14 January 2025).
- WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Available online: https://www.who.int/publications/i/item/9789241509565 (accessed on 13 September 2023).
- Gunthard, H.F.; Saag, M.S.; Benson, C.A.; del Rio, C.; Eron, J.J.; Gallant, J.E.; Hoy, J.F.; Mugavero, M.J.; Sax, P.E.; Thompson, M.A.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016, 316, 191–210. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States. 2014. Available online: https://stacks.cdc.gov/view/cdc/44064 (accessed on 13 September 2023).
- European AIDS Clinical Society (EACS). European AIDS Clinical Society Guidelines Version 8.0. Available online: https://www.eacsociety.org/media/guidelines_8_0-english_web.pdf (accessed on 13 September 2023).
- United Nations. The 17 Goals | Sustainable Development. Available online: https://sdgs.un.org/goals (accessed on 13 September 2023).
- Ogbuagu, O.; Ruane, P.J.; Podzamczer, D.; Salazar, L.C.; Henry, K.; Asmuth, D.M.; Wohl, D.; Gilson, R.; Shao, Y.; Ebrahimi, R.; et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs. emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: Week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV 2021, 8, e397–e407. [Google Scholar] [CrossRef]
- Bekker, L.G.; Das, M.; Karim, Q.A.; Ahmed, K.; Batting, J.; Brumskine, W.; Gill, K.; Harkoo, I.; Jaggernath, M.; Kigozi, G.; et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 2024, 391, 1179–1192. [Google Scholar] [CrossRef]
- Kelley, C.F.; Acevedo-Quiñones, M.; Agwu, A.L.; Avihingsanon, A.; Benson, P.; Blumenthal, J.; Brinson, C.; Brites, C.; Cahn, P.; Cantos, V.D.; et al. Twice-yearly lenacapavir for HIV prevention in men and gnder-diverse persons. N. Eng. J. Med. 2024. Online ahead of print. [Google Scholar] [CrossRef]
- Hiv, T.L. A game-changer for PrEP if access is adequate (Editorial). Lancet HIV 2024, 11, e567. [Google Scholar] [CrossRef]
- British Columbia Centre for Excellence in HIV/AIDS (BC-CfE). Therapeutic Guidelines for Antiretroviral (ARV) Treatment of Adult HIV Infection. BC-CfE. Available online: https://bccfe.ca/bccfe-documents/therapeutic-guidelines-for-antiretroviral-arv-treatment-of-adult-hiv-infection/ (accessed on 10 December 2024).
- Olding, M.; Enns, B.; Panagiotoglou, D.; Shoveller, J.; Harrigan, P.R.; Barrios, R.; Kerr, T.; Montaner, J.S.G.; Nosyk, B. A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996–2015. J. Int. AIDS Soc. 2017, 20, 21941. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lima, V.D.; Brumme, Z.L.; Brumme, C.; Sereda, P.; Krajden, M.; Wong, J.; Guillemi, S.A.; Henry, B.; Hogg, R.S.; Barrios, R.; et al. The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. Curr. HIV/AIDS Rep. 2020, 17, 77–87. [Google Scholar] [CrossRef] [PubMed]
- Munasinghe, L.L.; Toy, J.; Lepik, K.J.; Moore, D.M.; Hull, M.; Bacani, N.; Sereda, P.; Barrios, R.; Montaner, J.S.G.; Lima, V.D.; et al. Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada. PLoS ONE 2023, 18, e0283025. [Google Scholar] [CrossRef]
- BCCDC Non-certified Practice Decision Support Tool: HIV Pre Exposure Prophylaxis (HIV PrEP). Available online: http://www.bccdc.ca/resource-gallery/Documents/Communicable-Disease-Manual/Chapter%205%20-%20STI/PrEP-DST.pdf (accessed on 25 February 2025).
- Biggerstaff, M.; Cauchemez, S.; Reed, C.; Gambhir, M.; Finelli, L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: A systematic review of the literature. BMC Infect. Dis. 2014, 14, 480. [Google Scholar] [CrossRef] [PubMed]
- Kim, D.; Ali, S.T.; Kim, S.; Jo, J.; Lim, J.-S.; Lee, S.; Ryu, S. Estimation of Serial Interval and Reproduction Number to Quantify the Transmissibility of SARS-CoV-2 Omicron Variant in South Korea. Viruses 2022, 14, 533. [Google Scholar] [CrossRef]
- May, R.M.; Anderson, R.M. Transmission dynamics of HIV infection. Nature 1987, 326, 137–142. [Google Scholar] [CrossRef] [PubMed]
- May, R.M.; Anderson, R.M. The transmission dynamics of human immunodeficiency virus (HIV). Philos. Trans. R. Soc. Lond. B Biol. Sci. 1988, 321, 565–607. [Google Scholar] [CrossRef]
- Delamater, P.L.; Street, E.J.; Leslie, T.F.; Yang, Y.T.; Jacobsen, K.H. Complexity of the Basic Reproduction Number (R(0)). Emerg. Infect. Dis. 2019, 25, 1–4. [Google Scholar] [CrossRef]
- Amundsen, E.J.; Stigum, H.; Rottingen, J.A.; Aalen, O.O. Definition and estimation of an actual reproduction number describing past infectious disease transmission: Application to HIV epidemics among homosexual men in Denmark, Norway and Sweden. Epidemiol. Infect. 2004, 132, 1139–1149. [Google Scholar] [CrossRef]
- Chen, Y.H.; Farnham, P.G.; Hicks, K.A.; Sansom, S.L. Estimating the HIV Effective Reproduction Number in the United States and Evaluating HIV Elimination Strategies. J. Public Health Manag. Pract. 2022, 28, 152–161. [Google Scholar] [CrossRef]
- Lima, V.D.; Rozada, I.; Grebely, J.; Hull, M.; Lourenco, L.; Nosyk, B.; Krajden, M.; Yoshida, E.; Wood, E.; Montaner, J.S.G. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? PLoS ONE 2015, 10, e0143836. [Google Scholar] [CrossRef] [PubMed]
- Inglesby, T.V. Public Health Measures and the Reproduction Number of SARS-CoV-2. JAMA 2020, 323, 2186–2187. [Google Scholar] [CrossRef]
- Lima, V.D.; Zhu, J.; Barrios, R.; Toy, J.; Joy, J.B.; Williams, B.G.; Granich, R.; Wu, Z.; Wong, J.; Montaner, J.S.G. Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: A population-level programme evaluation. Lancet HIV 2024, 11, e461–e469. [Google Scholar] [CrossRef] [PubMed]
- British Columbia Centre for Excellence in HIV/AIDS (BC-CfE). Drug Treatment Program. Available online: https://www.bccfe.ca/drug-treatment-program#:~:text=The%20Drug%20Treatment%20Program%20 (accessed on 26 June 2023).
- Public Health Agency of Canada. Estimates of HIV Incidence, Prevalence and Canada’s Progress on Meeting the 90-90-90 HIV Targets. 2020. Available online: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html#a4.3 (accessed on 26 July 2023).
- St-Jean, M.; Dong, X.; Tafessu, H.; Moore, D.; Honer, W.G.; Vila-Rodriguez, F.; Sereda, P.; Hogg, R.S.; Patterson, T.L.; Salters, K.; et al. Overdose mortality is reducing the gains in life expectancy of antiretroviral-treated people living with HIV in British Columbia, Canada. Int. J. Drug Policy 2021, 96, 103195. [Google Scholar] [CrossRef] [PubMed]
- Johnston, K.M.; Levy, A.R.; Lima, V.D.; Hogg, R.S.; Tyndall, M.W.; Gustafson, P.; Briggs, A.; Montaner, J. Expanding access to HAART: A cost effective approach for treating and preventing HIV. AIDS 2010, 24, 1929–1935. [Google Scholar] [CrossRef]
- Granich, R.; Kahn, J.G.; Bennett, R.; Holmes, C.B.; Garg, N.; Serenata, C.; Sabin, M.L.; Makhlouf-Obermeyer, C.; Mack, C.D.F.; Williams, P.; et al. Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011–2050. PLoS ONE 2012, 7, e30216. [Google Scholar] [CrossRef]
- Walensky, R.; Ross, E.L.; Kumarasamy, N.; Wood, R.; Noubary, F.; Paltiel, A.D.; Nakamura, Y.M.; Godbole, S.V.; Panchia, R.; Sanne, I.; et al. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. N. Engl. J. Med. 2013, 369, 1715–1725. [Google Scholar] [CrossRef]
- Nosyk, B.; Min, J.E.; Lima, V.D.; Hogg, R.S.; Montaner, J.; STOP HIV/AIDS Study Group. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: A modelling study. Lancet HIV 2015, 2, 393–400. [Google Scholar] [CrossRef]
- Gomez, G.B.; Borquez, A.; Case, K.K.; Wheelock, A.; Vassall, A.; Hankins, C. The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies. PLoS Med. 2013, 10, e1001401. [Google Scholar] [CrossRef]
- Buchbinder, S.P.; Glidden, D.V.; Liu, A.Y.; McMahan, V.; Guanira, J.V.; Mayer, K.H.; Goicochea, P.; Grant, R.M. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: A secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect. Dis. 2014, 14, 468–475. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- HIV in Canada: 2023 Surveillance Highlights. Available online: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-2023-surveillance-highlights-infographic.html (accessed on 14 January 2025).
- The Urgency is Now, AIDS at a Crossroads; 2024 Global AIDS Update. Available online: https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update_en.pdf (accessed on 14 January 2025).
- Hatzakis, A.; Sypsa, V.; Paraskevis, D.; Nikolopoulis, G.; Tsiara, C.; Micha, K.; Panopoulos, A.; Malliori, M.; Psichogiou, M.; Pharris, A.; et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: The ARISTOTLE programme. Addiction 2015, 110, 1453–1467. [Google Scholar] [CrossRef] [PubMed]
- Psichogiou, M.; Giallouros, G.; Pantavou, K.; Pavlitina, E.; Papadopoulou, M.; Williams, L.D.; Hadjikou, A.; Kakalou, E.; Skoutelis, A.; Protopapas, K.; et al. Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of the network-based intervention. AIDS Care 2019, 31, 1376–1383. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Montaner, J.S.G.; Lima, V.D.; Salters, K.A.; Toy, J.; Joy, J.B.; Guillemi, S.; Barrios, R. Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS. Trop. Med. Infect. Dis. 2025, 10, 75. https://doi.org/10.3390/tropicalmed10030075
Montaner JSG, Lima VD, Salters KA, Toy J, Joy JB, Guillemi S, Barrios R. Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS. Tropical Medicine and Infectious Disease. 2025; 10(3):75. https://doi.org/10.3390/tropicalmed10030075
Chicago/Turabian StyleMontaner, Julio S. G., Viviane D. Lima, Kate A. Salters, Junine Toy, Jeffrey B. Joy, Silvia Guillemi, and Rolando Barrios. 2025. "Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS" Tropical Medicine and Infectious Disease 10, no. 3: 75. https://doi.org/10.3390/tropicalmed10030075
APA StyleMontaner, J. S. G., Lima, V. D., Salters, K. A., Toy, J., Joy, J. B., Guillemi, S., & Barrios, R. (2025). Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS. Tropical Medicine and Infectious Disease, 10(3), 75. https://doi.org/10.3390/tropicalmed10030075